Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: J. S. Gaynor x
  • Refine by Access: All Content x
Clear All Modify Search

Objective

To identify risk factors associated with acquired megaesophagus in dogs.

Design

Case-control study.

Animals

136 dogs with acquired megaesophagus (case dogs); 272 dogs from the general hospital population and 151 dogs that underwent thyroid-stimulating hormone response tests (control dogs). All dogs were more than 6 months old.

Procedure

Medical records of dogs in which megaesophagus was diagnosed during a 10-year period were reviewed. Inclusion criteria included regurgitation or vomiting, onset of clinical signs at more than 6 months of age, and radiographic evidence of generalized esophageal dilatation. Dogs with intra- or extraesophageal obstructive disease, brain stem disease, or neck trauma were excluded from analyses. Statistical analyses included odds ratios, 95% confidence intervals, and two-tailed t-tests. Control dogs were frequency matched to case dogs on the basis of year of diagnosis.

Results

Dogs with megaesophagus ranged from 0.75 to 18 years old (mean, 8.1 years) and were significantly older and heavier than control dogs. More males than females were affected, but sex and reproductive status were not associated with megaesophagus. German Shepherd Dogs, Golden Retrievers, and Irish Setters were at increased risk for developing megaesophagus. Peripheral neuropathies, laryngeal paralysis, acquired myasthenia gravis, esophagitis, and chronic or recurrent gastric dilatation with or without volvulus were associated with an increased risk of developing megaesophagus. Hypothyroidism was not associated with megaesophagus.

Clinical Implications

Dogs with acquired megaesophagus should be evaluated for peripheral neuropathies, laryngeal paralysis, acquired myasthenia gravis, esophagitis, and chronic or recurrent gastric dilatation with or without volvulus. These dogs may be evaluated for hypothyroidism; however, this study did not reveal a clear association between hypothyroidism and acquired megaesophagus. (J Am Vet Med Assoc 1997;211:1406–1412)

Free access
in Journal of the American Veterinary Medical Association

Summary:

The effects of propofol on anesthetic induction were evaluated in 40 dogs anesthetized with isoflurane. Propofol is a rapidly acting, nonbarbiturate drug that induces anesthesia of ultrashort duration with iv administration. Four preanesthetic regimens were used: anesthesia without preanesthetic drugs; or with preanesthetic administration of acepromazine (0.1 mg/kg of body weight, im), diazepam (0.2 mg/kg, iv), or acepromazine (0.02 mg/kg) and butorphanol (0.4 mg/kg) im. Heart rate, systolic arterial blood pressure (sap), respiration, quality of induction and recovery, and adverse effects were recorded. Intravenous propofol administration induced a variable period of apnea in 34 of 40 dogs. Cyanosis (in 2 dogs) and signs of pain on injection (in 3 dogs) were infrequently observed during induction. One dog developed ventricular premature depolarizations after propofol administration. Venous CO2 tension increased and pH decreased immediately after propofol administration, regardless of preanesthetic regimen. The sap significantly (P < 0.05) decreased after propofol administration in dogs treated with acepromazine (sap, 178 mm of Hg before vs 128 mm of Hg after propofol) and with acepromazine/butorphanol (sap, 184 mm of Hg before vs 98 mm of Hg after propofol). When used for induction, propofol induces anesthetic-related adverse effects, some of which can be minimized by preanesthetic medication. Recovery characteristics varied with preanesthetic medication, independent of propofol administration.

Free access
in Journal of the American Veterinary Medical Association